Ranbaxy Australia

Ranbaxy Australia was the Australian subsidiary of Ranbaxy Laboratories, a prominent Indian multinational pharmaceutical company. The company operated as a key provider of generic medicines in the Australian market, offering a diverse portfolio that included anti-infectives, cardiovascular drugs, and treatments for central nervous system disorders. Headquartered in Macquarie Park, New South Wales, Ranbaxy Australia focused on increasing the accessibility of affordable healthcare through its extensive range of off-patent medications. In March 2015, the global parent company was acquired by Sun Pharmaceutical Industries in a transaction valued at approximately $4 billion. Following this acquisition, Ranbaxy's Australian operations were integrated into Sun Pharma's local business, and the Ranbaxy brand was subsequently retired in the region. The legacy of the company continues through the broad range of generic products now marketed under the Sun Pharma name in Australia.